Acute Hepatic Porphyria

Acute hepatic porphyria (AHP) refers to a family of rare, genetic diseases characterized by potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life.1,4,7

**AHP is composed of four types, each associated with distinct enzyme defects in the heme biosynthesis pathway in the liver:**1,3,7

- **Acute intermittent porphyria (AIP)**
- **Hereditary coproporphyria (HCP)**
- **Variegate porphyria (VP)**
- **ALA dehydratase-deficiency porphyria (ADP)**

In the United States and Europe, ~5,000 people experience one or more attacks annually2,18

~1,000 people suffer frequent and severe attacks, requiring multiple hospitalizations each year1,2,18

Due to the debilitating attacks and chronic symptoms of AHP, attack prevention is an important part of disease management.1

**AHP Symptoms Significantly Impact Quality of Life**

AHP is a rare disease disproportionately impacting female patients of working and childbearing age. Symptoms of AHP vary widely and usually first occur between the ages of 18-45.3

Severe, diffuse abdominal pain, vomiting/nausea, dark/reddish urine8,13,14

Confusion, anxiety, seizures, hallucinations, fatigue1,4,5

Muscle weakness, numbness, respiratory failure4,5

Blistering lesions, erosions or ulcers of sun-exposed skin (primarily in VP and HCP)1,13,14,15

**Misdiagnosis of AHP is Common**

The nonspecific nature of AHP signs and symptoms can often lead to misdiagnoses of other more common conditions, such as viral gastroenteritis, Irritable Bowel Syndrome (IBS), and addiction withdrawal.

Patients afflicted with AHP are often misdiagnosed or remain undiagnosed for up to 15 years.8,10,12,18

Delays in diagnosis can result in a higher burden of disease, which may include unnecessary surgeries, medical complications, and respiratory paralysis.

AHP has been associated with long-term complications and comorbidities such as hypertension, chronic kidney disease or liver disease, including hepatocellular carcinoma (liver cancer).5,6,8,10,22
In people with the genetic defect for AHP, one of the enzymes in the pathway that creates heme is deficient. Certain triggers can impact the pathway and can cause an increase of ALAS1 (aminolevulinic acid synthase 1).1,3,7

In patients with AHP, this increase in ALAS1 results in the buildup of neurotoxic intermediates – aminolevulinic acid (ALA) and porphobilinogen (PBG) – throughout the body.8,16,17 ALA and PBG are harmful to nerve cells and are factors associated with the attacks and disease manifestations characteristic of AHP.8,16,17,20,21

1. Puy H, Gouya L, Deybach JC. Lancet. 2010;375(9718):924-937.
2. ORPHANET: The Porphyria Consortium. Acute hepatic porphyria.
3. Bissell DM, Anderson KE, Bonkovsky HL. N Engl J Med. 2017;377(9):962-972.
4. Simon A, Pomplius F, Querbes W, et al. Patient. 2018;11(5):527-537.
5. Pischik E, Kauppinen R. Appl Clin Genet. 2015;8:201-214.
6. Balwani M. Clin Adv Hematol Oncol. 2016;14(11):858-861.
7. Balwani M, Desnick RJ. Blood. 2012;120(23):4496-4504.
8. Bonkovsky HL, Maddukuri VC, Yacizi C, et al. Am J Med. 2014;127(12):1233-1241.
9. Stein PE, Badminton MH, Barth JH, et al. Clin Med (Lond). 2012;12(3):293-294.
10. Pischik E, Bulyanitsa A, Kazakov V, Kauppinen R. J Neurol. 2004;251(12):1538-1541.
11. Kondo M, Yano Y, Shrivata M, Ura G, Sassa S. Int J Hematol. 2004;79:448-456.
12. Alhadhel M, Saleh N, Alenazi H, Raffoe-Bonnie H. Neuropsychiatr Dis Treat. 2014;10:2135-2137.
13. Gouya L, Ventura P, Balwani M, et al. Hepatology. 2020;71(3):1546-1558.
14. Naik H, Stoecker M, Sanderson S, Badminton M, Desnick RJ. Mol Genet Metab. 2016;119(3):278-283.
15. Szlendak U, Bykowska K, Lipniacka A. Adv Clin Exp Med. 2016;25(2):361-368.
16. Besur S, Hau W, Schmeltzer P, Bonkovsky HL. Metabolites. 2014;4(4):977-1006.
17. Ramanujam VMS, Anderson KE. Curr Protoc Hum Genet. 2015;86:17.20.1-17.20.26.
18. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. J Inherit Metab Dis. 2013;36(5):849-857.
19. Ko Ji, Murray S, Merek M, et al. Real-World Analysis of Symptoms, Diagnostic Patterns, and Provider Perspective on Acute Hepatic Porphyrias. Presented at: American College of Gastroenterology 2018 Annual Scientific Meeting; Oct. 5-10, 2018.
20. Pallet N, Karras A, Theret E, Gouya L, Karim Z, Puy H. Clin Kidney J. 2018;11(2):191-197.
21. Power K, Manceau H, Karim Z, et al. Mol Genet Metabol. 2018;128:1-6.
22. Bissell DM, Wang B. J Clin Transl Hepatol. 2015;3(1):17-26.